151 related articles for article (PubMed ID: 38566987)
1. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
[TBL] [Abstract][Full Text] [Related]
2. Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma.
Nylund P; Nikkarinen A; Ek S; Glimelius I
Front Immunol; 2024; 15():1373269. PubMed ID: 38566987
[TBL] [Abstract][Full Text] [Related]
3. Single nucleotide variants in immune-response genes and the tumor microenvironment composition predict progression of mantle cell lymphoma.
Assis-Mendonça GR; Fattori A; Rocha RM; Lourenço GJ; Delamain MT; Nonogaki S; de Lima VCC; Colleoni GWB; de Souza CA; Soares FA; Lima CSP; Vassallo J
BMC Cancer; 2021 Mar; 21(1):209. PubMed ID: 33648463
[TBL] [Abstract][Full Text] [Related]
4. Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphoma.
Nikkarinen A; Lokhande L; Amini RM; Jerkeman M; Porwit A; Molin D; Enblad G; Kolstad A; Räty R; Hutchings M; Weibull CE; Hollander P; Ek S; Glimelius I
Blood Adv; 2023 Sep; 7(18):5304-5313. PubMed ID: 37389827
[TBL] [Abstract][Full Text] [Related]
5. Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma.
Jiang VC; Liu Y; Jordan A; Leeming A; McIntosh J; Huang S; Zhang R; Cai Q; Chen Z; Li Y; Che Y; Nie L; Karlsson I; Mårtensson L; Kovacek M; Teige I; Frendéus B; Wang M
J Hematol Oncol; 2022 Apr; 15(1):42. PubMed ID: 35410313
[TBL] [Abstract][Full Text] [Related]
6. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.
Tarockoff M; Gonzalez T; Ivanov S; Sandoval-Sus J
Curr Oncol Rep; 2022 Oct; 24(10):1313-1326. PubMed ID: 35639332
[TBL] [Abstract][Full Text] [Related]
7. MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial.
Jerkeman M; Kolstad A; Hutchings M; Pasanen A; Meriranta L; Niemann CU; Kragh Jørgensen RR; El-Galaly TC; Riise J; Leppä S; Christensen JH; Sonnevi K; Pedersen LB; Wader KF; Glimelius I
Blood Adv; 2024 Jan; 8(2):407-415. PubMed ID: 38113470
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies.
Ruella M; Korell F; Porazzi P; Maus MV
Nat Rev Drug Discov; 2023 Dec; 22(12):976-995. PubMed ID: 37907724
[TBL] [Abstract][Full Text] [Related]
9. MYC overexpression: adding another piece to the puzzle of high-risk mantle cell lymphoma.
Kumar A
Haematologica; 2024 Apr; 109(4):1027-1028. PubMed ID: 37855068
[No Abstract] [Full Text] [Related]
10. Enhanced tumor immunotherapy by polyfunctional CD19-CAR T cells engineered to secrete anti-CD47 single-chain variable fragment.
Qiu Y; Liao P; Wang H; Chen J; Hu Y; Hu R; Zhang H; Li Z; Cao M; Yang Y; Li M; Xie X; Li Y
Int J Biol Sci; 2023; 19(15):4948-4966. PubMed ID: 37781520
[TBL] [Abstract][Full Text] [Related]
11. Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia.
Aroldi A; Mauri M; Ramazzotti D; Villa M; Malighetti F; Crippa V; Cocito F; Borella C; Bossi E; Steidl C; Scollo C; Voena C; Chiarle R; Mologni L; Piazza R; Gambacorti-Passerini C
J Cell Mol Med; 2023 Oct; 27(20):3053-3064. PubMed ID: 37654003
[TBL] [Abstract][Full Text] [Related]
12. MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and
Rodrigues JM; Hollander P; Schmidt L; Gkika E; Razmara M; Kumar D; Geisler C; Grønbæk K; Eskelund CW; Räty R; Kolstad A; Sundström C; Glimelius I; Porwit A; Jerkeman M; Ek S
Haematologica; 2024 Apr; 109(4):1171-1183. PubMed ID: 37646663
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression).
Scheubeck G; Jiang L; Hermine O; Kluin-Nelemans HC; Schmidt C; Unterhalt M; Rosenwald A; Klapper W; Evangelista A; Ladetto M; Jerkeman M; Ferrero S; Dreyling M; Hoster E
Leukemia; 2023 Sep; 37(9):1887-1894. PubMed ID: 37495776
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]